A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

作者：C. Warren Olanow, Stanley Fahn, Manfred D. Muenter, Harold L. Klawans, Howard I. Hurtig, Matthew Stern, Ira Shoulson, Roger Kurlan, J. David Grimes, Joseph J. Jankovic, Margaret M. Maier Hoehn, Charles H. Markham, R. Duvisin, OSCAR M. REINMUTH, Hubert A. Leonard, Eric J. Ahlskog, Robert Feldman, Linda Ann Hershey, Melvin D. Yahr · 发表于：Movement Disorders · 年份：1994 · DOI：10.1002/mds.870090107 · 被引用次数：204 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Parkinson's Disease and Spinal Disorders、Nerve Injury and Rehabilitation

Three hundred and seventy-six subjects with advanced Parkinson's disease participated in a prospective, double-blind placebo-controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet. At 6 months, patients randomized to pergolide had a statistically significant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of "off" hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.